| AOD-9604 | Regulatory Limbo | Suspended | Removed from Category 2 in September 2024 after the original nominator withdrew. The FDA's advisory committee voted against adding it to the 503A bulks list in December 2024. Not currently scheduled for further review. |
| BPC-157 | Category 2 | Prohibited | Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review BPC-157 on July 23, 2026, for potential addition to the 503A bulks list. The use under review: gut inflammation and inflammatory bowel conditions (ulcerative colitis). No formal rule change yet. Not FDA approved. Prohibited by WADA (added 2022) under S0, with no medical exemption available for athletes. |
| CJC-1295 (without DAC) | Regulatory Limbo | Suspended | Removed from Category 2 in September 2024 but not yet added to Category 1. Not currently scheduled for FDA pharmacy compounding advisory committee review. |
| DSIP | Category 2 | Prohibited | Category 2 (listed by the FDA as Emideltide). The FDA's pharmacy compounding advisory committee is scheduled to review DSIP on July 24, 2026, for potential addition to the 503A bulks list. The uses under review: opioid withdrawal, chronic insomnia, and narcolepsy. Originally discovered in 1974, one of the oldest peptides on the July 2026 agenda. |
| Epitalon | Category 2 | Prohibited | Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review Epitalon on July 24, 2026, for potential addition to the 503A bulks list. The use under review: insomnia. |
| GHK-Cu (Topical) | Category 1 | Legal | On the FDA 503A Category 1 list for topical and oral use. Legally available through compounding pharmacies. |
| GHK-Cu (Injection) | Category 2 | Prohibited | Injectable form is Category 2 and cannot be legally compounded. Expected to move to Category 1 under the February 2026 HHS announcement, but no formal rule yet. |
| Ipamorelin | Regulatory Limbo | Suspended | Removed from Category 2 in September 2024 but not yet added to Category 1. Not currently scheduled for FDA pharmacy compounding advisory committee review. |
| Kisspeptin | Category 2 | Prohibited | Category 2. The FDA's advisory committee voted against adding kisspeptin to the 503A bulks list in December 2024. Not currently scheduled for further review. Faces a harder path than most compounds because of the prior rejection. |
| KPV | Category 2 | Prohibited | Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review KPV on July 23, 2026, for potential addition to the 503A bulks list. The uses under review: wound healing and inflammatory conditions. |
| MOTS-c | Category 2 | Prohibited | Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review MOTS-c on July 23, 2026, for potential addition to the 503A bulks list. The uses under review: obesity and osteoporosis. Prohibited by WADA as a metabolic modulator. |
| Selank | Regulatory Limbo | Suspended | Removed from Category 2 in September 2024 when the original nominator withdrew. Not currently scheduled for FDA pharmacy compounding advisory committee review. Approved as a prescription medication in Russia. |
| Semax | Category 2 | Prohibited | Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review Semax on July 24, 2026, for potential addition to the 503A bulks list. The uses under review: stroke recovery (cerebral ischemia), migraine, and nerve pain (trigeminal neuralgia). Approved as a prescription medication in Russia. |
| Sermorelin | Category 1 | Legal | Originally FDA-approved in 1997 as Geref for pediatric growth hormone deficiency; brand discontinued in 2008 for manufacturing reasons. Sermorelin was never on the September 2023 Category 2 list and is legally compoundable by 503A pharmacies today as a component of a previously FDA-approved drug. Prohibited under WADA S2 as an explicitly named GHRH analogue, with no therapeutic use exemption available for athletes. |
| TB-500 | Category 2 | Prohibited | Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review TB-500 on July 23, 2026, for potential addition to the 503A bulks list. The use under review: wound healing. Prohibited by WADA under S2.3 since 2011, with a 4-year ban for athletes testing positive. |
| Thymosin Alpha-1 | Regulatory Limbo | Suspended | Removed from Category 2 in September 2024 after the original nominator withdrew. The FDA's advisory committee voted against adding it to the 503A bulks list in December 2024. Not currently scheduled for further review. Approved in 30+ countries for immune modulation. |